Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response makes many kidney-risk claims that are not explicitly supported by the provided FDA label excerpts, including mechanistic and risk-amplifier statements (e.g., dehydration, crystallization mechanism, IV vs oral likelihood, and concentration-related crystallization). While the label supports renal impairment/need for hydration/dose adjustment and reports renal failure with acyclovir, the response overstates causality and probability rankings beyond the supplied text.
Category Scores
Accurate Statements
Acyclovir can affect kidney function.
Supported by label text indicating renal failure observed and that half-life/total body clearance depend on renal function (CLINICAL PHARMACOLOGY: Adults With Impaired Renal Function; WARNINGS/ADVERSE REACTIONS: renal failure observed).
The risk of acyclovir-related kidney injury is higher in people with preexisting kidney disease (renal impairment).
PRECAUTIONS: dosage adjustment recommended for renal impairment and adequate hydration maintained; WARNINGS/ADVERSE REACTIONS: renal failure observed.
Staying well hydrated is a prevention step when acyclovir is prescribed to prevent kidney problems.
PRECAUTIONS: 'Adequate hydration should be maintained.'
Correct dosing / renal dose adjustment affects kidney safety with acyclovir.
PRECAUTIONS: 'Dosage adjustment is recommended... to patients with renal impairment'; CLINICAL PHARMACOLOGY: dosage adjustment recommended for reduced renal function; DOSAGE AND ADMINISTRATION: renal dosing modifications.
Acyclovir accumulation may be mitigated by dose adjustment in reduced kidney function.
Label supports dosage adjustment for reduced renal function (CLINICAL PHARMACOLOGY; DOSAGE AND ADMINISTRATION for renal impairment). The specific stated purpose to 'lower the risk of accumulating' is not explicitly worded, but the concept is consistent with the supported dose-adjustment rationale.
Oral acyclovir can still pose a risk of kidney issues.
WARNINGS: 'Renal failure, in some cases resulting in death, has been observed with acyclovir therapy'; ADVERSE REACTIONS: 'Renal failure' listed under Urogenital.
Unsupported Statements
The risk of acyclovir affecting kidney function is higher if drug levels build up in the bloodstream.
Provided label excerpts do not explicitly link higher blood levels to increased kidney injury risk (they describe dose-related concentration changes and renal impairment effects on clearance/half-life, but no explicit risk linkage).
The risk of acyclovir-related kidney injury is higher when the patient is dehydrated.
The label recommends adequate hydration, but the provided excerpts do not state that dehydration specifically increases kidney injury risk.
Acyclovir can cause kidney injury mainly through crystallization in the renal tubules.
No provided label text describes a crystallization mechanism in renal tubules.
Acyclovir crystallization in renal tubules can reduce urine flow.
No provided label text describes crystallization or reduced urine flow.
Acyclovir crystallization in renal tubules can lead to acute kidney problems.
While renal failure is described, the crystallization mechanism and explicit causal linkage are not provided in the excerpts.
Crystallization-related kidney injury from acyclovir is more likely when the drug is concentrated.
No label text states concentration-dependent crystallization risk.
Kidney clearance impairment increases the likelihood of acyclovir crystallization and kidney injury.
Label supports altered clearance/half-life and dose adjustment in renal impairment, but not crystallization or that increased likelihood is due to crystallization.
Dehydrated people (from vomiting, diarrhea, fever, or poor fluid intake) are more likely to develop kidney-related side effects from acyclovir.
No label excerpt specifies those dehydration causes or ties them to kidney risk.
Acyclovir-related kidney injury may present with decreased urine output.
The provided ADVERSE REACTIONS excerpt lists renal failure, renal pain, elevated BUN/creatinine, and hematuria, but does not mention decreased urine output.
Acyclovir-related kidney injury may present with swelling in the legs/feet.
Peripheral edema is listed generally, but the provided excerpt does not connect it specifically to acyclovir-related kidney injury.
Acyclovir-related kidney injury may present with unusual fatigue.
The excerpt lists 'malaise' as a frequent adverse event in herpes zoster trials, but does not link fatigue specifically to kidney injury.
Doctors typically confirm kidney injury from acyclovir with blood tests such as creatinine and other measures of kidney function.
The label excerpt includes elevated creatinine/BUN among observed findings, but does not state diagnostic practice such as clinicians 'typically confirm' kidney injury with these tests.
The likelihood of kidney issues is generally greater with IV acyclovir.
The provided label excerpts discuss IV acyclovir indication and precautions, but do not state a general increase in kidney issue likelihood with IV vs oral.
The likelihood of kidney issues is generally greater with higher-dose acyclovir regimens.
The label excerpts show dose-related concentration changes and report renal failure observed, but do not explicitly state that likelihood of kidney issues is generally greater with higher-dose regimens.
Higher drug exposure from IV or higher-dose acyclovir can increase the chance of kidney crystal formation and toxicity.
No label excerpt mentions kidney crystal formation mechanism; it also does not explicitly link higher exposure to crystal formation/toxicity.
Oral acyclovir is usually lower risk when taken as directed and with adequate fluids.
The label supports hydration and dose adjustment, but the provided excerpts do not contain the explicit 'usually lower risk' comparative statement.
Contradictions
Important Omissions
The response does not address contraindications (hypersensitivity to acyclovir or valacyclovir) present in the label.
Importance:
Moderate
The response does not address that renal failure has been observed with acyclovir therapy and that TTP/HUS has occurred in immunocompromised patients receiving acyclovir (WARNINGS section).
Importance:
Moderate
The response does not reflect the label instruction that acyclovir oral suspension is intended for oral ingestion only (administration restriction).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported mechanistic and risk-probability claims (e.g., crystallization mechanism, dehydration/IV vs oral/general likelihood statements) could mislead relative risk understanding beyond what the provided label excerpts support, despite some correct label-supported guidance on hydration and renal dose adjustment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple key kidney-risk claims are mechanistically detailed and/or framed as probability/likelihood comparisons (dehydration, crystallization in renal tubules, IV vs oral, higher-dose regimens) that are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to label-supported content in the provided excerpts: renal impairment and need for dosage adjustment, maintaining adequate hydration, and that renal failure (with elevated BUN/creatinine/renal findings) has been observed. Remove or rephrase unsupported mechanistic and probability ranking statements not explicitly present in the label.